[go: up one dir, main page]

SG11202107510SA - Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells - Google Patents

Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Info

Publication number
SG11202107510SA
SG11202107510SA SG11202107510SA SG11202107510SA SG11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA SG 11202107510S A SG11202107510S A SG 11202107510SA
Authority
SG
Singapore
Prior art keywords
hbv
hla
peptides
virus
cells
Prior art date
Application number
SG11202107510SA
Inventor
Yang Cheng
Evan Newell
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11202107510SA publication Critical patent/SG11202107510SA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761Hepatitis B
    • G01N33/5762Hepatitis B core antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
SG11202107510SA 2019-01-11 2020-01-13 Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells SG11202107510SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201900299V 2019-01-11
PCT/SG2020/050017 WO2020145901A1 (en) 2019-01-11 2020-01-13 Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Publications (1)

Publication Number Publication Date
SG11202107510SA true SG11202107510SA (en) 2021-08-30

Family

ID=71522288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107510SA SG11202107510SA (en) 2019-01-11 2020-01-13 Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Country Status (5)

Country Link
US (1) US12414990B2 (en)
EP (1) EP3908591A4 (en)
CN (1) CN113939527B (en)
SG (1) SG11202107510SA (en)
WO (1) WO2020145901A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1083956S1 (en) * 2018-12-10 2025-07-15 Icahn School Of Medicine At Mount Sinai Display screen with a graphical user interface
CN116364188A (en) * 2023-03-30 2023-06-30 南开大学 A system for uncoupling exhausted T cells in the tumor microenvironment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
ZA926440B (en) * 1991-08-26 1993-06-07 Scripps Research Inst Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus.
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc Hla-binding peptides and their uses
WO2009136874A1 (en) 2008-05-09 2009-11-12 Agency For Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
CN102286075A (en) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 Hepatitis B virus surface antigen immunodominance HLA-A*1101 restricted cytotoxic T lymphocyte (CTL) epitope and use thereof
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
JP2016507520A (en) * 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Stabilized hepatitis B core polypeptide
JP6743154B2 (en) * 2016-01-12 2020-08-19 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) Means and methods for treating HBV
US11576932B2 (en) * 2016-03-31 2023-02-14 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
MX2022003658A (en) * 2019-09-30 2022-04-25 Gilead Sciences Inc VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND METHODS TO TREAT HBV.
WO2023146978A2 (en) * 2022-01-26 2023-08-03 Memorial Sloan-Kettering Cancer Center Systems and methods for determining t-cell cross-reactivity between antigens

Also Published As

Publication number Publication date
WO2020145901A1 (en) 2020-07-16
US20230087348A1 (en) 2023-03-23
US12414990B2 (en) 2025-09-16
CN113939527B (en) 2025-10-28
CN113939527A (en) 2022-01-14
EP3908591A1 (en) 2021-11-17
EP3908591A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
IL269927A (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
IL323352A (en) Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
SG10201914029RA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2016055534A3 (en) Combination therapy of hbv and hdv infection
IL275429A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
EP3439696A4 (en) THERAPEUTIC VACCINE FOR HEPATITIS B VIRUS (HBV) USING HBV NUCLEOCAPSIDIC ANTIGEN
SG11202107510SA (en) Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
IL288019A (en) Compositions and methods for treating hepatitis b virus (hbv) infection
SG11202005710YA (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
MY191515A (en) Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof
IL255366A0 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3319997A4 (en) IMMUNOGENIC COMPOSITIONS BASED ON HEPATITIS C VIRUS AND METHODS OF USE
NZ751943A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
IL290924A (en) Hepatitis b virus vaccines
EA201890187A1 (en) RECOMBINANT VIRUS-LIKE PARTICLES (VLP) WITH THE USE OF THE PROTEIN GROUP ANTIGEN (GAG) OF THE BUCK IMMUNODEFICIENCY
IL287227A (en) Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
EP4499684A4 (en) Compositions and methods for inducing an immune response against EPSTEIN-BARR virus
WO2016141201A3 (en) Rational vaccine design for hepatitis c virus
PT3491139T (en) Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
HK40074161A (en) Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
HK40039588A (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
HK40046103A (en) Hepatitis c virus peptide compositions and methods of use thereof
HK40039938A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines